KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Other Non-Current Liabilities (2016 - 2026)

West Pharmaceutical Services has reported Other Non-Current Liabilities over the past 18 years, most recently at $87.6 million for Q1 2026.

  • Quarterly Other Non-Current Liabilities rose 33.33% to $87.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $87.6 million through Mar 2026, up 33.33% year-over-year, with the annual reading at $75.2 million for FY2025, 20.9% up from the prior year.
  • Other Non-Current Liabilities was $87.6 million for Q1 2026 at West Pharmaceutical Services, up from $75.2 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $87.6 million in Q1 2026 and troughed at $33.9 million in Q3 2022.
  • The 5-year median for Other Non-Current Liabilities is $58.5 million (2023), against an average of $59.2 million.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 62.54% in 2023 and later grew 3.76% in 2024.
  • Tracing WST's Other Non-Current Liabilities over 5 years: stood at $51.6 million in 2022, then rose by 13.37% to $58.5 million in 2023, then increased by 6.32% to $62.2 million in 2024, then grew by 20.9% to $75.2 million in 2025, then rose by 16.49% to $87.6 million in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $87.6 million, $75.2 million, and $75.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.